Evolus Phase III European – Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint
Evolus (NASDAQ:EOLS) a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced the presentation of data from the European and Canadian Phase III EVB-003 head-to-head comparative trial demonstrating that its investigational prabotulinumtoxinA 900 kilodalton (kDa) neuromodulator met its primary endpoint of non-inferiority at Day 30 in subjects …
Evolus (NASDAQ:EOLS) a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced the presentation of data from the European and Canadian Phase III EVB-003 head-to-head comparative trial demonstrating that its investigational prabotulinumtoxinA 900 kilodalton (kDa) neuromodulator met its primary endpoint of non-inferiority at Day 30 in subjects with moderate to severe glabellar lines, also known as “frown lines,” compared to onabotulinumtoxinA (Botox®).
As quoted in the press release:
The results were presented today in a poster titled “A Multicenter Phase III Study Comparing prabotulinumtoxinA and onabotulinumtoxinA for the Treatment of Glabellar Lines” by Dr. Patricia Ogilvie, M.D., dermatologist and Principal Investigator of the study, at the 2018 Aesthetic & Anti-Aging Medicine World Congress (AMWC), being held April 4-7 in Monte-Carlo, Monaco. The results presented at AMWC expand upon the initial results presented at the American Academy of Dermatology (AAD) annual meeting in February 2018.
“Analysis of this study presented at AMWC shows that prabotulinumtoxinA met its primary endpoint in efficacy as well as its secondary endpoints. In particular, the secondary endpoint of subject satisfaction is important because it represents the opinions of consumers who underwent the treatment,” commented Patricia Ogilvie, M.D. “Based on these findings, we believe that prabotulinumtoxinA represents a compelling and innovative option for the aesthetic treatment of glabellar lines.”
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1827.54 | +0.47 | |
Silver | 21.15 | +0.03 | |
Copper | 3.74 | 0.00 | |
Palladium | 1879.51 | +6.50 | |
Platinum | 911.26 | +4.32 | |
Oil | 107.06 | +2.79 | |
Heating Oil | 4.24 | +0.02 | |
Natural Gas | 6.17 | -0.07 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Featured stocks
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.